Navigation Links
Biotech Company Relocates to State-of-the-Art Facility

HAMILTON, N.J., Jan. 4, 2011 /PRNewswire/ -- VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease-based targets or its partners' targets, announced today its relocation to a brand-new, state-of-the-art facility in Hamilton, NJ in Mercer County.

VENENUM Biodesign was established with the mission to improve patients' lives through the discovery of new therapeutic compounds. They are committed to building platforms for drug discovery research from novel targets to preclinical implementation. VENENUM Biodesign, a company within the Genesis Biotechnology Group, is located in "Einstein's Alley," the research and technology corridor in Hamilton, New Jersey. Their facility is easily accessible to other academic medical centers, biotech, and pharmaceutical companies in the New York, New Jersey, and Pennsylvania area.

This new facility is a unique blend of upscale office space with state-of-the-art laboratory facilities designed with a specialized floor plan to accommodate the Biodesign compound collection which includes 5.5 million proprietary compounds (the "ECLiPS" collection), six newly designed VENENUM Targeted Libraries (VTLs), and approximately 80,000 compounds from commercial sources. This small molecule collection is one of the largest in the world and, combined with state-of-the-art UHTS capabilities, is a powerful tool to generate quality platforms for drug discovery.

There are expansive laboratories to accommodate mammalian and yeast cell culture, siRNA technology, protein engineering and production, cellular reagent generation, structural biology, and in vitro assay and in vivo model development. VENENUM Biodesign's new facility has been engineered to specifically accommodate their well-published and experienced Target Biology department which identifies and validates novel targets. They are currently completing additional laboratory space immediately adjacent to the Target Biology Division to accommodate a growing Medicinal Chemistry team which implements and executes Hit-to-Lead and Lead Optimization programs.

According to Dr. Maria Webb, Chief Scientific Officer (CSO), "Our intention is to use our drug discovery capabilities to develop our own novel targets into therapeutic products as well as to provide access of our core capabilities to other companies and research institutions."

To find out more, please visit Webb, Ph.D.Chief Scientific Officer (CSO)mwebb@venenumbiodesign.com609.570.1048  This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference
2. Interleukin Genetics, Inc. to Present at Biotech Showcase 2011
3. Reportlinker Adds Financial Health of Biotechnology and Drugs Industry in India and China
4. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
5. New Second Edition of Biotechnology and the Federal Circuit Examines the Courts Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases
6. Biotech Guru G. Steven Burrill Offers his Predictions on What Lies Ahead for the Biotech Industry in 2011
7. BioCrossroads Invests in Innovative Biotech Targeting Challenging Diseases
8. Reportlinker Adds Nanobiotechnologies- applications, markets and companies
9. Bunker Hill Community College Wins Major Endorsement for Biotechnology Courses
10. TriLink BioTechnologies Launches CleanAmp™ 7-deaza-dGTP for GC-rich Target Amplification
11. Reportlinker Adds Nanobiotechnology: Applications and Global Markets
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group ... professionals from Central America and abroad for the first Iberoamerican Convention on Aesthetic ... 17-19, 2016. Testart will present and discuss new trends in anti-aging stem cell ...
(Date:11/30/2015)... radiology technique shows promise for helping morbidly obese patients lose ... presented today at the annual meeting of the Radiological Society ... --> --> Gastric artery embolization ... way to stop bleeding in emergency situations, but the idea ... is new. Mubin Syed , M.D., interventional radiologist ...
(Date:11/30/2015)... 30, 2015 Harvard Apparatus Regenerative Technology, ... company developing bioengineered organ implants for life-threatening conditions, ... The NASDAQ Stock Market that it has regained ... letter noted that as a result of the ... exceeded $1.00 per share for more than ten ...
(Date:11/30/2015)...  Champions Oncology, Inc. (CSBR), engaged in the development ... development and use of oncology drugs, today announced that ... presenting at the LD MICRO Investor Conference on Wednesday, ... The conference, held at the Luxe Sunset Bel Air ... will feature 200 small/micro-cap companies and is expected to ...
Breaking Biology Technology:
(Date:11/18/2015)... 2015 --> ... market report titled  Gesture Recognition Market - Global Industry ... 2021. According to the report, the global gesture recognition market was valued ... reach US$29.1 bn by 2021, at a CAGR of ... America dominated the global gesture recognition market ...
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):